太极集团 (600129.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

6.4x

EV/EBITDA

19.5x

Market Cap

CNY 7.84B

MomentumView details →

1D Return

−5.71%

YTD Return

−23.55%

RSI (14)

39.6

ValuationView details →

P/E (Fwd)

6.4x

EV/EBITDA

19.5x

Market Cap

CNY 7.84B

RSI (14)

39.6

MomentumView details →

1D Return

−5.71%

YTD Return

−23.55%

ProfitabilityView details →

Gross Margin

31.33%

Net Margin

1.09%

EBITDA Margin

6.20%

ROE (TTM)

3.13%

ROA (TTM)

0.75%

Asset Turnover

0.70x

GrowthView details →

Revenue YoY

−7.32%

EPS YoY

+166.03%

FCF YoY

+90.15%

Revenue CAGR 3Y

−9.42%

EPS CAGR 3Y

−29.95%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.04

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.49x

Current Ratio

0.74x

Quick Ratio

0.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

+200.00%

Financials snapshotView financials →

Revenue (TTM)

10.20B

Net Income (TTM)

111.65M

Op. CF (TTM)

346.97M

Next earningsOct 23, 2026 →

Latest newsMore news →

Taiji Group announced its 2026 half-year results: net profit attributable to shareholders was 87.8573 million yuan, down 36.70% year-on-year.10d ago

Taiji Group's controlling subsidiary Southwest Pharmaceutical received a drug registration certificate from the National Medical Products Administration for butorphanol tartrate injection, in specifications of 1ml:1mg and 2ml:4mg, for the treatment of cancer pain and postoperative pain.26d ago

Similar companies

华北制药600812.SH 上海谊众688091.SH SSY Group Limited02005.HK 汇宇制药-W688553.SH 鲁抗医药600789.SH Sihuan Pharmaceutical Holdings Group Ltd.00460.HK Find similar companies →

Latest newsMore news →

Taiji Group announced its 2026 half-year results: net profit attributable to shareholders was 87.8573 million yuan, down 36.70% year-on-year.10d ago Taiji Group's controlling subsidiary Southwest Pharmaceutical received a drug registration certificate from the National Medical Products Administration for butorphanol tartrate injection, in specifications of 1ml:1mg and 2ml:4mg, for the treatment of cancer pain and postoperative pain.26d ago